Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Clin Microbiol ; 52(7): 2680-3, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24808242

ABSTRACT

Dientamoeba fragilis is a common enteropathogen of humans. Recently a cyst stage of the parasite was described in an animal model; however, no cyst stage has been described in detail from clinical samples. We describe both cyst and precystic forms from human clinical samples.


Subject(s)
Dientamoeba/cytology , Dientamoebiasis/parasitology , Spores, Protozoan/cytology , Dientamoeba/physiology , Humans , Microscopy , Spores, Protozoan/physiology
2.
Parasitology ; 138(7): 819-23, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21524324

ABSTRACT

Dientamoeba fragilis is a pathogenic protozoan parasite that is implicated as a cause of human diarrhoea. A case-controlled study was conducted to determine the clinical signs associated with D. fragilis infection in children presenting to a Sydney Hospital. Treatment options are also discussed. Stool specimens were collected from children aged 15 years or younger and analysed for the presence of D. fragilis. In total, 41 children were included in the study along with a control group. Laboratory diagnosis was performed by microscopy of permanently stained, fixed faecal smears and by real-time PCR. Gastrointestinal symptoms were present in 40/41 (98%) of these children with dientamoebiasis, with diarrhoea (71%) and abdominal pain (29%) the most common clinical signs. Chronic gastrointestinal symptoms were present in 2% of cases. The most common anti-microbial used for treatment was metronidazole (n=41), with complete resolution of symptoms and clearance of parasite occurring in 85% of cases. A treatment failure rate occurred in 15% of those treated with metronidazole. Follow-up treatment comprised of an additional course of metronidazole or iodoquinol was needed in order to achieve complete resolution of infection and symptoms in this group. This study demonstrates the pathogenic potential of D. fragilis in children and as such it is recommended that all laboratories must routinely test for this organism and treat if detected.


Subject(s)
Dientamoebiasis/diagnosis , Dientamoebiasis/drug therapy , Metronidazole/therapeutic use , Abdominal Pain/etiology , Adolescent , Antiprotozoal Agents/therapeutic use , Australia/epidemiology , Case-Control Studies , Child , Child, Preschool , Diarrhea/etiology , Dientamoeba/physiology , Dientamoebiasis/complications , Dientamoebiasis/epidemiology , Dientamoebiasis/pathology , Feces/parasitology , Female , Humans , Infant , Iodoquinol/therapeutic use , Male , Treatment Outcome
3.
J Clin Microbiol ; 49(1): 257-62, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21048004

ABSTRACT

The aim of this study was to describe the first development and evaluation of a multiplex tandem PCR (MT-PCR) assay for the detection and identification of 4 common pathogenic protozoan parasites, Cryptosporidium spp., Dientamoeba fragilis, Entamoeba histolytica, and Giardia intestinalis, from human clinical samples. A total of 472 fecal samples submitted to the Department of Microbiology at St. Vincent's Hospital were included in the study. The MT-PCR assay was compared to four real-time PCR (RT-PCR) assays and microscopy by a traditional modified iron hematoxylin stain. The MT-PCR detected 28 G. intestinalis, 26 D. fragilis, 11 E. histolytica, and 9 Cryptosporidium sp. isolates. Detection and identification of the fecal protozoa by MT-PCR demonstrated 100% correlation with the RT-PCR results, and compared to RT-PCR, MT-PCR exhibited 100% sensitivity and specificity, while traditional microscopy of stained fixed fecal smears exhibited sensitivities and specificities of 56% and 100% for Cryptosporidium spp., 38% and 99% for D. fragilis, 47% and 97% for E. histolytica, and 50% and 100% for G. intestinalis. No cross-reactivity was detected in 100 stool samples containing various other bacterial, viral, and protozoan species. The MT-PCR assay was able to provide rapid, sensitive, and specific simultaneous detection and identification of the four most important diarrhea-causing protozoan parasites that infect humans. This study also highlights the lack of sensitivity demonstrated by microscopy, and thus, molecular methods such as MT-PCR must be considered the diagnostic methods of choice for enteric protozoan parasites.


Subject(s)
Cryptosporidium/isolation & purification , Dientamoeba/isolation & purification , Entamoeba histolytica/isolation & purification , Giardia lamblia/isolation & purification , Parasitology/methods , Polymerase Chain Reaction/methods , Protozoan Infections/diagnosis , Cryptosporidium/genetics , Dientamoeba/genetics , Entamoeba histolytica/genetics , Feces/parasitology , Giardia lamblia/genetics , Humans , Microscopy , Protozoan Infections/parasitology , Sensitivity and Specificity
4.
Clin Microbiol Rev ; 23(4): 795-836, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20930074

ABSTRACT

There are many neglected nonenteric protozoa able to cause serious morbidity and mortality in humans, particularly in the developing world. Diseases caused by certain protozoa are often more severe in the presence of HIV. While information regarding neglected tropical diseases caused by trypanosomatids and Plasmodium is abundant, these protozoa are often not a first consideration in Western countries where they are not endemic. As such, diagnostics may not be available in these regions. Due to global travel and immigration, this has become an increasing problem. Inversely, in certain parts of the world (particularly sub-Saharan Africa), the HIV problem is so severe that diseases like microsporidiosis and toxoplasmosis are common. In Western countries, due to the availability of highly active antiretroviral therapy (HAART), these diseases are infrequently encountered. While free-living amoebae are rarely encountered in a clinical setting, when infections do occur, they are often fatal. Rapid diagnosis and treatment are essential to the survival of patients infected with these organisms. This paper reviews information on the diagnosis and treatment of nonenteric protozoal diseases in immunocompromised people, with a focus on patients infected with HIV. The nonenteric microsporidia, some trypanosomatids, Toxoplasma spp., Neospora spp., some free-living amoebae, Plasmodium spp., and Babesia spp. are discussed.


Subject(s)
Immunocompromised Host , Protozoan Infections/immunology , Protozoan Infections/parasitology , Africa South of the Sahara , Amoeba/immunology , Amoeba/pathogenicity , Antiretroviral Therapy, Highly Active , Female , HIV Infections/parasitology , HIV Infections/physiopathology , Humans , Plasmodium/immunology , Plasmodium/pathogenicity , Pregnancy , Protozoan Infections/diagnosis , Protozoan Infections/therapy , Trypanosomatina/immunology , Trypanosomatina/pathogenicity
5.
Parasitology ; 137(13): 1867-78, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20609278

ABSTRACT

Dientamoeba fragilis is a pathogen of the human gastrointestinal tract that is a common cause of diarrhoea. A paucity of knowledge on the in vitro cultivation and cryopreservation of Dientamoeba has meant that few studies have been conducted to investigate its biology. The objective of this study was to define, for the first time, in vitro culture conditions able to support the long-term in vitro growth of Dientamoeba. Also, we aimed to define a suitable method for cryopreserving viable Dientamoeba trophozoites. A modified BD medium, TYGM-9, Loeffler's slope medium, Robinson's medium, Medium 199, Trichosel and a Tritrichomonas fetus medium were compared, using cell counts, for their ability to support the growth of D. fragilis at various temperatures and atmospheric conditions. Loeffler's slope medium supported significantly better growth compared to other media. A temperature of 42°C and a microaerophilic atmosphere were also optimum for Dientamoeba growth. To our knowledge, this is the first study to describe and compare different culture media and conditions for the growth of clinical isolates of D. fragilis. This new technology will aid the development of diagnostics for dientamoebiasis as well as facilitate large-scale sequencing projects that will fast track molecular studies on D. fragilis.


Subject(s)
Cryopreservation/methods , Culture Media , Dientamoeba/growth & development , Dientamoebiasis/parasitology , Parasitology/methods , Animals , DNA, Protozoan/analysis , DNA, Protozoan/isolation & purification , Dientamoeba/genetics , Dientamoeba/isolation & purification , Dientamoeba/metabolism , Humans , Polymerase Chain Reaction , Sequence Analysis, DNA , Temperature
6.
Clin Microbiol Rev ; 22(4): 634-50, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19822892

ABSTRACT

Globally, the number of immunosuppressed people increases each year, with the human immunodeficiency virus (HIV) pandemic continuing to spread unabated in many parts of the world. Immunosuppression may also occur in malnourished persons, patients undergoing chemotherapy for malignancy, and those receiving immunosuppressive therapy. Components of the immune system can be functionally or genetically abnormal as a result of acquired (e.g., caused by HIV infection, lymphoma, or high-dose steroids or other immunosuppressive medications) or congenital illnesses, with more than 120 congenital immunodeficiencies described to date that either affect humoral immunity or compromise T-cell function. All individuals affected by immunosuppression are at risk of infection by opportunistic parasites (such as the microsporidia) as well as those more commonly associated with gastrointestinal disease (such as Giardia). The outcome of infection by enteric protozoan parasites is dependent on absolute CD4(+) cell counts, with lower counts being associated with more severe disease, more atypical disease, and a greater risk of disseminated disease. This review summarizes our current state of knowledge on the significance of enteric parasitic protozoa as a cause of disease in immunosuppressed persons and also provides guidance on recent advances in diagnosis and therapy for the control of these important parasites.


Subject(s)
Immunocompromised Host , Intestinal Diseases, Parasitic/parasitology , Opportunistic Infections/parasitology , Protozoan Infections/parasitology , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/immunology , AIDS-Related Opportunistic Infections/parasitology , AIDS-Related Opportunistic Infections/pathology , Antiprotozoal Agents/therapeutic use , Humans , Intestinal Diseases, Parasitic/drug therapy , Intestinal Diseases, Parasitic/immunology , Intestinal Diseases, Parasitic/pathology , Opportunistic Infections/drug therapy , Opportunistic Infections/immunology , Opportunistic Infections/pathology , Protozoan Infections/diagnosis , Protozoan Infections/drug therapy , Protozoan Infections/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...